Navigation Links
Seattle Genetics Highlights Data on its Proprietary Antibody-Drug,Conjugate Technology at AACR

rom the "Technology" section of the company's website at www.seattlegenetics.com.

About Seattle Genetics

Seattle Genetics is a biotechnology company developing monoclonal antibody-based therapies for the treatment of multiple types of cancer, including lymphoma, multiple myeloma, leukemia and solid tumors. The company has an exclusive worldwide license agreement with Genentech to develop and commercialize SGN-40. Seattle Genetics also has three other proprietary programs in ongoing clinical trials: SGN-33, SGN-35 and SGN-30. In addition, the company has developed proprietary antibody-drug conjugate (ADC) technology comprised of highly potent synthetic drugs and stable linkers for attaching the drugs to monoclonal antibodies. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Genentech, Bayer, CuraGen, Progenics and MedImmune, as well as an ADC co-development agreement with Agensys. More information can be found at www.seattlegenetics.com.

Certain of the statements made in this press release are forward-looking, such as those, among others, relating to the potential therapeutic potential of Seattle Genetics' product candidates and ADC technology. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks related to adverse clinical results as our product candidates move into and advance in clinical trials, risks inherent in early stage development and failure by Seattle Genetics' collaborators to advance product candidates incorporating its technology. More information about the risks and uncertainties faced by Seattle Genetics is contained in Seattle Genetics' filings with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
2. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
3. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
6. Myriad Genetics Presents Tumor Origin Technology at AACR
7. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
8. Myriad Genetics Presents Azixas Mode of Action at AACR
9. Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
Post Your Comments:
(Date:9/4/2008)...imumab to be Presented, PRINCETON, N.J., Sept. 4 ...MEDX ) announced today that nine clinical abstract...ntibody, in melanoma are scheduled to be,the subje...ropean Society,for Medical Oncology (ESMO) being h...e following abstracts will include updated one-yea...
(Date:9/3/2008)...hildren Studied. Wrong,Conclusions Reached., NIXA...s for Disease,Control and Prevention (CDC) study r...MMR vaccine and autism. The National Autism Associ... the growing public concern over a,vaccine-autism ... design,and methodology., For years, parents have...
(Date:9/3/2008).../- Artelis SA and,Selexis SA announce...tibody,production with the achievement of manufact...rd level was accomplished by applying two highly,i...ble Selexis CHO,production cell line rapidly gener...using their proprietary Selexis Genetic Elements(T...
(Date:9/3/2008)...idence Pycnogenol(R) Lowers Joint, Pain, Symptoms;...essation of the Extrac...ng to the Center for,Disease Control (CDC), osteoa... the rise. A new study published in the August jou...R), bark extract from the French maritime pine,tre...
Breaking Medicine Technology:Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 2Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 3CDC Misses Target With Flawed MMR/Autism Study 2Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 2Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter 3Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 2Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 3Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 4Agendia BV Announces That its Chief Research Officer Laura van t Veer has Received a 2007 Breast Cancer Research Foundation Award 1403 1Agendia BV Announces That its Chief Research Officer Laura van t Veer has Received a 2007 Breast Cancer Research Foundation Award 1403 2Elbit Medical Imaging Ltd Announces Definitive Agreements for a Large Scale Luxury Mixed Use Project in Bangalore India 1401 1Elbit Medical Imaging Ltd Announces Definitive Agreements for a Large Scale Luxury Mixed Use Project in Bangalore India 1401 2Elbit Medical Imaging Ltd Announces Definitive Agreements for a Large Scale Luxury Mixed Use Project in Bangalore India 1401 3Elbit Medical Imaging Ltd Announces Definitive Agreements for a Large Scale Luxury Mixed Use Project in Bangalore India 1401 4SPO Medical Announces Major Sales Milestone 1399 1SPO Medical Announces Major Sales Milestone 1399 2SPO Medical Announces Major Sales Milestone 1399 3Patient Enrollment Complete in First Trial to Compare Physiologic Guidance vs Angiographic Guidance of Stent Deployment in Patients with Multivessel 587 1Patient Enrollment Complete in First Trial to Compare Physiologic Guidance vs Angiographic Guidance of Stent Deployment in Patients with Multivessel 587 2
... - Pfizer announced today,that Lipitor (atorvastat...ke, coronary heart disease events and major corona...nown coronary heart disease,but who had experience...acebo. The results are from a new analysis of the ... in Cholesterol Levels,(SPARCL) trial, and were pr...
...re/ -- Novagali Pharma, an,emerging pharmaceutical...itive results of its pivotal phase III clinical tr...tudy of Vekacia(R) in,children suffering from Vern...n Congress of ophthalmology (AACO) held from June ...evere form of chronic allergic conjunctivitis,char...
Other Medicine Technology:Lipitor Reduced the Risk of Coronary Events by Half and Stroke by,Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who,Experienced a Recent Stroke 2Lipitor Reduced the Risk of Coronary Events by Half and Stroke by,Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who,Experienced a Recent Stroke 3Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 2Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 3Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 4
(Date:9/5/2008)...Most can be controlled, but you need to know what ...Sept. 5 (HealthDay News) -- If you are one of the ...rgies, there is nowhere in the United States that ... a new report shows. , Allergies don,t only hap... seasons as well. In the fall, the most challengin...
(Date:9/5/2008)... FRANKLIN, Mass., Sept. 5 /PRNewswire/ -- Arthr...he developer of less-invasive joint,resurfacing sy...m the U.S.,FDA to begin its pivotal investigation ...he FDA stated that "there are no outstanding safet...initiation., Arthrosurface has been evaluating th...
(Date:9/5/2008)... ,The National Institute of Diabetes and Digesti...al Institutes of Health (NIH), announces awards to...orative studies of urologic chronic pelvic pain di...nd prostate. The total research investment for the...million. , "The launch of this novel research ef...
(Date:9/5/2008)... MIDLOTHIAN, Va., Sept. 5 /PRNewswire/ -- On Sa...ll be featured on the Oxygen Network show Today,s,...ARI is highlighted as a,leading medical device com...s, with effective nebulizers and compressors that ... "Our vision is to improve the lives of those aff...
Breaking Medicine News(10 mins):Health News:No Place Safe From Allergies 2Health News:Arthrosurface HemiCAP(R) Focal Knee Resurfacing Implant Receives FDA Approval to Move into Final Investigational Stage 2Health News:NIH launches unique effort to advance study of urologic chronic pelvic pain disorders 2Health News:NIH launches unique effort to advance study of urologic chronic pelvic pain disorders 3Health News:PARI Respiratory Equipment Featured on Oxygen Network 2
...prize, Pauline Ashley Prize 2007 was awarded to a ...// in the human brain that could help to single ou...a party or get together and also responsible for t...ch circumstances. It has been noted that inabilit...
...ints from Doctors about huge backlogs of patients ...edical Association//, who have begun investigating...s such as hysterectomies, colonoscopies and gallbl...ack burner, with patients on a long-winding waitin...
...ut to embark upon a health revolution that offers ...for paraplegics to walk again.// This is the opin...ted seven medical advances which they consider wil...ogy stem cell science, and bionic innovation are a...
...malities were found in a particular brain area of ...g to a study conducted// at the Laboratory for Cog...ogical Studies. Williams syndrome is a rare genet... music and, will therefore spend hours listening t...
Other Medicine News:Health News:Tune Your Brain to Hear Another in a Noisy Ambience 2Health News:Tune Your Brain to Hear Another in a Noisy Ambience 3Health News:Tune Your Brain to Hear Another in a Noisy Ambience 4Health News:Age of Medical Miracles has come upon us 2
...d multidimensional diagnostic system that elevates...t topography systems which scan the surface of the...ver 9000 data points in 1.5 seconds to meticulousl...yze elevation and curvature measurements on both t...
Trusted technology. Precisely measured. Zywave® II Wavefront Aberrometer offers precision diagnostics, measuring refractive error by identifying the total aberrations of the eye. ,As part of the
ZYMAR™ ophthalmic solution is an anti-infective prescription eye drop that your doctor may instruct you to use if you have an eye infection caused by bacteria. Bacterial conjunctivitis is the e
RELIEF® eye drops quickly remove redness due to dust, smoke & other pollutants and provide protection against further irritation from wind and the sun. This unique formula contains the effective
Medicine Products: